TNDM · Tandem Diabetes Care
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $14.00
Note written ·
Price against the kill line
43.4% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $14.00, on record since 10 November 2026; only a weekly close settles it. The shares are down 9.8% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $14.00, which would send the shares back toward the $12.82 closing low of 15 May 2026. A cut to 2026 sales guidance below $1.065 billion, or no tubeless Mobi clearance announced by 31 December 2026, would also show the case failing.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 284
- Revenue, change on a year (%)
- +13.8
- Gross margin (%)
- 56.5
- Operating margin (%)
- −0.8
- Free cash flow, four quarters ($M)
- −36.3
- Net cash, cash less debt ($M)
- −160
- Enterprise value to sales (×)
- 1.5
- Free-cash-flow yield (%)
- −2.6
All filed numbers
What Tandem Diabetes Care reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 284 | +13.8 | 56.5 | −0.8 |
| first filed | 255 | +5.8 | 56.9 | −5.4 |
| first filed | 247 | +5.5 | 55.3 | −7.1 |
| first filed | 290 | +2.7 | 57.7 | 2.9 |
| first filed | 249 | +2.2 | 53.9 | −9.2 |
| first filed | 241 | +8.5 | 52.3 | −21.5 |
| Pre-tax income ($M) | −7.7 |
| Net income ($M) four quarters: −49.2 | −7.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +3.0 |
| Operating cash flow ($M) | −14.6 |
| Capital spending ($M) | 21.7 |
| Free cash flow ($M) | −36.3 |
| Cash and short-term investments ($M) | 443 |
| Debt ($M) non-current long-term debt | 603 |
| Net cash, cash less debt ($M) | −160 |
| Deferred revenue ($M) −14.7% on a year | 15.9 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 180 |
| Inventory ($M) | 143 |
| Shareholders' equity ($M) | 135 |
| Market value ($M) | 1,401 |
| Enterprise value, market value plus net debt ($M) | 1,561 |
| Enterprise value to sales (×) | 1.5 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 10.4 |
| Free-cash-flow yield (%) | −2.6 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 21.6% of shares outstanding sold short, 6.9 days of average trading to cover, +12.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $33K |
| 12 monthsfrom | $0 | $37K |
The thesis
Tandem Diabetes Care is modestly more likely to beat the S&P 500 over the next three months. Chief executive John Sheridan said on the 5 November 2026 earnings call that the tubeless version of its Mobi insulin pump is "in the late stages of FDA review" and that the company expects approval in the fourth quarter. Clearance announced by 31 December 2026 settles the call.
The third quarter supports the operating case. Sales were $283.7 million, up 14% from a year earlier, and gross margin was 57%, inside the 56%–57% range guided for 2026 (company 8-K, 5 November 2026). The operating loss narrowed to $2.4 million from $22.9 million.
The same call lowered the 2027 expectation. Chief financial officer Leigh Vosseller called a mid-to-high single-digit sales increase for 2027 "probably a really fair starting point", when asked about consensus near 12%, and said pharmacy-channel sales headwinds would extend into 2027. Full commercial availability of tubeless Mobi is planned for the first half of 2027, with limited customer use before that.
The shares closed at $17.51 on 12 November 2026, 22.9% below the 3-month reference close of $22.72 on 14 August 2026. That price already reflects the reduced 2027 growth framing: the shares sit 40.9% below the 52-week high of $29.65 set intraday on 24 February 2026.
Bullish and bearish views on Tandem Diabetes Care, Inc.
The bull case on Tandem Diabetes Care, Inc. (TNDM), in brief: third quarter beat on sales and loss. The bear case: 2027 growth framing came in below consensus.
Bull case
- Third quarter beat on sales and loss. Sales of $283.690 million beat the $265.922 million consensus estimate, and the $0.10 loss per share beat the $0.25 loss expected (Benzinga, 5 November 2026). U.S. sales were $191.0 million (up 9%) and international sales $92.6 million (up 26%), per the 8-K.
- Profitability is turning. Gross margin was 57% versus 54% a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, adjusted) was $18.0 million, or 6% of sales (8-K, 5 November 2026).
- Tubeless clearance has a stated timetable. Tandem submitted the 510(k) (the FDA's standard device-clearance filing) in the second quarter, and Sheridan said on 5 November 2026 that approval is expected in the fourth quarter. Tandem's 2026 guidance excludes tubeless Mobi sales, so clearance adds to the range.
- Guidance held with margins on target. Tandem reaffirmed 2026 sales of $1.065 billion–$1.085 billion, gross margin of 56%–57% and adjusted EBITDA margin of 5%–6% (8-K, 5 November 2026).
- Post-report analyst targets sit above the price. Wells Fargo kept Overweight with a $25 target and Barclays kept Equal-Weight with a $20 target, both on 6 November 2026 (Benzinga).
Bear case
- 2027 growth framing came in below consensus. The CFO's mid-to-high single-digit starting point for 2027 compares with the near-12% consensus raised on the 5 November 2026 call. Management said it was too early to give numbers.
- The pharmacy shift is slower than planned. On the 5 November 2026 call, management put 2026 pharmacy share of pump shipments and of sales at 10% to 12% each and said the transition pace is "more gradual than we initially anticipated".
- Guidance was reaffirmed, not raised. The 2026 sales range is unchanged after a quarter that beat the $265.922 million estimate. Benzinga listed the consensus for the year at $1.072 billion.
- Leadership changes before the product decision. Jeannette Bankes becomes president and chief executive on 16 November 2026, succeeding Sheridan, who retires at the end of 2026 (company announcement, 5 November 2026).
- Debt has nearly doubled. Convertible senior notes, net, were $603.4 million at 30 September 2026 versus $310.0 million at 31 December 2025. Cash, equivalents and short-term investments were $443.1 million versus $292.7 million at year-end 2025 (8-K, 5 November 2026).
- The FDA has published no decision date. Clearance in the fourth quarter is the company's expectation. A slip into 2027 would remove the main product catalyst from the three-month window.
Price setup
The shares closed at $17.51 on 12 November 2026, after $18.77 on 11 November 2026 and $16.91 on 6 November 2026. The 50-day average is $17.41 and the 200-day average is $18.84 as of 12 November 2026, so the shares sit just above the first and below the second.
The 52-week high is $29.65 (intraday, 24 February 2026). The 52-week closing low is $12.82 on 15 May 2026. The close of $22.72 on 14 August 2026 is the price the shares must regain to reverse the three-month decline of 22.9%.
Tandem announced on 12 November 2026 that Health Canada approved a license amendment for the t:slim X2 pump. The company's headline gives no sales figure for it.
Catalysts ahead
- 16 November 2026: Jeannette Bankes becomes president and CEO. The new chief executive's first comments on tubeless timing, margins and spending are the next management read.
- 31 December 2026: End of the fourth quarter, when management expects FDA clearance of tubeless Mobi. No clearance announcement by this date would defeat the product-timing premise; the date is the company's expectation, not an FDA decision date.
- ~February 2027 (est.): Fourth-quarter and full-year 2026 report. Shows whether 2026 sales land inside the $1.065 billion–$1.085 billion guide and whether management gives a 2027 sales range.
What would change the view
A weekly close below $14.00, which would send the shares back toward the $12.82 closing low of 15 May 2026. A cut to 2026 sales guidance below $1.065 billion, or no tubeless Mobi clearance announced by 31 December 2026, would also show the case failing.
The risks this note tracks, each with what would confirm it:
- Tubeless Mobi clearance slips beyond 2026. Confirmed by: no company or FDA clearance announcement by 31 December 2026, or company guidance moving the launch into the second half of 2027.
- 2027 growth is set below the mid-to-high single-digit starting point. Confirmed by: a 2027 sales outlook below that range at the fourth-quarter report, or pharmacy share falling short of the 10% to 12% assumed for 2026.
- Growth or margin fades after a strong third quarter. Confirmed by: 2026 sales guidance cut below $1.065 billion or gross margin guidance below 56% at the fourth-quarter report.
- The CEO transition disrupts execution. Confirmed by: changed guidance, a delayed launch or senior departures reported after 16 November 2026.
- Convertible debt of $603.4 million limits financial flexibility if growth stalls. Confirmed by: a new financing or share issuance announcement, or cash falling below the $443.1 million reported on 30 September 2026.
What it trades with
Tandem trades with other insulin-delivery and glucose-monitoring companies. Insulet's Omnipod 5 holds the leading tubeless position (Drug Delivery Business, May 2026), so Insulet news bears on Tandem's tubeless prospects. Abbott's FreeStyle Libre 3 Plus integration ties Tandem's international rollout to Abbott's sensor supply. The convertible notes make the shares sensitive to credit conditions and to small-cap medical-device sentiment.
The evidence, claim by claim (8)
- Third-quarter 2026 sales were $283.7 million, up 14%, with a 57% gross margin versus 54% a year earlier and an operating loss of $2.4 million versus $22.9 million. Tandem Diabetes Care Q3 2026 results, Form 8-K · as of
- Tandem reaffirmed 2026 sales guidance of $1.065 billion–$1.085 billion, gross margin of 56%–57% and adjusted EBITDA margin of 5%–6%. Tandem Diabetes Care Q3 2026 results, Form 8-K · as of
- CEO John Sheridan said tubeless Mobi is in the late stages of FDA review and expected to be approved in the fourth quarter, with full commercial availability in the first half of 2027. Tandem Q3 2026 earnings call transcript · as of
- CFO Leigh Vosseller called a mid-to-high single-digit sales increase for 2027 a fair starting point; management put 2026 pharmacy share of pumps and of sales at 10% to 12%. Tandem Q3 2026 earnings call transcript · as of
- Q3 EPS of $(0.10) beat the $(0.25) estimate and sales of $283.690 million beat the $265.922 million estimate. Benzinga · as of
- Cash, equivalents and short-term investments were $443.1 million and long-term convertible senior notes, net, were $603.4 million at quarter end. Tandem Diabetes Care Q3 2026 results, Form 8-K · as of
- Wells Fargo kept Overweight with a $25 target; Barclays kept Equal-Weight and raised its target to $20. Benzinga analyst-action reports · as of
- Tandem appointed Jeannette Bankes as president and CEO effective 16 November 2026, succeeding John Sheridan. Tandem Diabetes Care company announcement · as of
Sources
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
AVTR
Avantor
Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
EMBC
Embecta
Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle…
See also · stocks to watch